- Home
- MRBK vs IMA Comparison
MRBK vs IMA Comparison
Compare MRBK & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- IMA
- Stock Information
- Founded
- MRBK 2004
- IMA 2019
- Country
- MRBK United States
- IMA United States
- Employees
- MRBK N/A
- IMA N/A
- Industry
- MRBK Major Banks
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRBK Finance
- IMA Health Care
- Exchange
- MRBK Nasdaq
- IMA Nasdaq
- Market Cap
- MRBK 177.5M
- IMA 159.1M
- IPO Year
- MRBK 2017
- IMA N/A
- Fundamental
- Price
- MRBK $15.16
- IMA $9.14
- Analyst Decision
- MRBK Buy
- IMA
- Analyst Count
- MRBK 2
- IMA 0
- Target Price
- MRBK $17.50
- IMA N/A
- AVG Volume (30 Days)
- MRBK 64.7K
- IMA 41.0K
- Earning Date
- MRBK 10-23-2025
- IMA 01-01-0001
- Dividend Yield
- MRBK 3.29%
- IMA N/A
- EPS Growth
- MRBK 69.83
- IMA N/A
- EPS
- MRBK 1.61
- IMA N/A
- Revenue
- MRBK $106,330,000.00
- IMA $4,300,000.00
- Revenue This Year
- MRBK $25.14
- IMA N/A
- Revenue Next Year
- MRBK $8.08
- IMA N/A
- P/E Ratio
- MRBK $9.46
- IMA N/A
- Revenue Growth
- MRBK 17.11
- IMA N/A
- 52 Week Low
- MRBK $10.89
- IMA $7.95
- 52 Week High
- MRBK $17.33
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- MRBK 48.05
- IMA N/A
- Support Level
- MRBK $15.35
- IMA N/A
- Resistance Level
- MRBK $15.71
- IMA N/A
- Average True Range (ATR)
- MRBK 0.20
- IMA 0.00
- MACD
- MRBK -0.08
- IMA 0.00
- Stochastic Oscillator
- MRBK 4.51
- IMA 0.00
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.